PFE · News · 20260825N

Guidance / Outlook

PFIZER INC · 2026-08-25 · Importance 46 · Surprise 60

Pfizer provided full-year 2026 EPS guidance following second-quarter results that exceeded revenue and earnings expectations. Third-party reporting characterizes the guidance as consistent with a mature biopharmaceutical company. The outlook highlights oncology pipeline execution, including the Elrexfio trial, as a potential source of future growth.

Key facts

• PFIZER INC provided full-year EPS guidance described as aligning with a mature biopharmaceutical firm. source
• PFIZER INC beat Q2 revenue and EPS expectations (Q2 beat stated in the report). source
• Bank of Nova Scotia reduced its PFIZER INC holdings by 13.4% during the quarter. source
• PFIZER INC's future growth was reported as anticipated from its oncology pipeline, exemplified by the Elrexfio trial. source
• PFIZER INC's dividend yield was stated as 6.1%. source
• PFIZER INC stock rose by 2.15% to $28.57 on the cited trading day. source
• PFIZER INC closed the cited trading day 0.61% below its 52-week high. source
• PFIZER INC shares owned by Bank of Nova Scotia after the sale: 4,423,296 shares. source